Indraprastha Medical Corporation working capital

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

10.57×	10.57×	11.50×	13.43×	15.93×	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
23.10×	23.10×	18.01×	18.57×	22.67×
178.48×	178.48×	207.59×	199.80×	185.09×
−144.81×	−144.81×	−178.08×	−167.80×	−146.49×
5.36×	6.00×	5.37×	8.73×	11.76×
1.61×	1.61×	1.72×	1.95×	1.98×
0.91×	0.91×	0.97×	1.61×	1.68×
0.63×	0.63×	0.64×	1.04×	0.96×

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

INDRAMEDCO₹300.00

Indraprastha Medical Corporation Limited

· Pharma & Health

₹ CrorePeersARTEMISMED SHALBY GKSL GPTHEALTH LOTUSEYE DRAGARWQ KMCSHIL KOVAIMcap ₹2,750 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Inventory Days (DIO)	15.93	13.43	11.50	10.57	10.57
Receivable Days (DSO)	22.67	18.57	18.01	23.10	23.10
Payable Days (DPO)	185.09	199.80	207.59	178.48	178.48
Cash Conversion Cycle (days)	-146.49	-167.80	-178.08	-144.81	-144.81
Working Capital Turnover	11.76	8.73	5.37	6.00	5.36
Asset Turnover	1.98	1.95	1.72	1.61	1.61
Cash Conversion (CFO/Net Income)	1.68	1.61	0.97	0.91	0.91
CFO/EBITDA	0.96	1.04	0.64	0.63	0.63

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.